ERBB2 and breast carcinoma: Additional studies indicated that trastuzumab and docetaxel exhibit a synergistic effect when administered together, markedly improving the response rate of HER-2-overexpressing breast cancer by increasing the time to progression, as well as the median survival time (30–33).